Iran's President Pezeshkian reaffirms Tehran won't abandon its nuclear program while rejecting nuclear weapon ambition, as European powers prepare for talks amid threat of U.N. sanctions.

Dubbed the "eclipse of the century", lucky sky watchers in some parts of the world will enjoy a whopping 6 minutes and 21 seconds of totality – the duration of total obscuration of the Sun.

Want to learn to code and write your first Java program? Here's a quick and fun Java programming tutorial that will have your running your first Java program in less than 10 minutes.

UN watchdog and intercepted Iran call undermine Trump’s boasts about ending nuke program Facilities could produce enriched uranium for weapons in ‘months’, International Atomic Energy Agency ...

President Donald Trump said on Friday that he expects Iran to open itself to international inspection to verify that it doesn’t restart its nuclear program.

Jakarta EE, a working group hosted by the Eclipse Foundation, today announced the general availability of the Jakarta EE 11 Platform, the latest version of its enterprise Java platform. The new ...

The Japan–World Bank Partnership Program focuses on the dissemination of findings of grant-financed analytical studies, seminars, and conferences on emerging development challenges and solutions. It ...

Iran’s nuclear program remains a top focus for inspectors from the International Atomic Energy Agency, particularly as any possible deal between Tehran and the United States over the program ...

Eclipse Private Wealth was in the inaugural class of Sanctuary's Enterprise Partner Program, developed to support the inorganic growth efforts of its Partner Firms.

This week's Java roundup for May 19th, 2025, features news highlighting: Java’s 30th birthday; the release of Hibernate ORM 7.0 and Hibernate Validator 9.0; the May 2025 edition of Open Liberty ...

SUN Bucks, a Summer EBT program, provides a one-time benefit payment for children from eligible households. Here's how to enroll and who's eligible.

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.